| Revenue growth | Reported -1.5% YoY; base business double-digit ex-lenalidomide NA |
|---|---|
| Margins | EBITDA 20.6% vs 26.7% Q2FY26; Q1 hit by ₹240 Cr provision |
| Demand visibility | Emerging Markets +24% YoY; India +17% YoY; NA down 23% |
Growth
Reported revenue -1.5% YoY, +7% QoQ. PAT -36% YoY but +109% QoQ off Q1's ₹240 Cr semaglutide provision hit.
Outlook
No numeric guidance given. Semaglutide API issue resolution 'on track'; Qdenga private launch H1 2027; M&A and in-licensing emphasis.
Risks
Semaglutide API out-of-spec batches; multiple Form 483 observations; lenalidomide erosion; lower API volume offtake; Europe pricing pressure.
Last quarter's promises, checked
Delivered
- EBITDA ~20% ex-semaglutide (Q2 guide) → 20.6% (= BEAT)
- EM growth north of 15% → EM +24% YoY (= BEAT)
Partly delivered
- NA double-digit base growth ex-lenalidomide → reported NA -23% YoY, base unquantified (= PARTIAL)
- Semaglutide root-cause fix by ~22-23 Sep → only 'on track', completion unconfirmed (= PARTIAL)
- FY27 capex ~₹1,800 Cr → H1 ~₹493 Cr, mixed basis (= PARTIAL)
Investor Presentation filed with BSE, NSE: DRREDDY. Summary written with AI assistance from the document.
Dr. Reddy's Laboratories Ltd: key numbers
- Share price
- ₹1,335.40
- Market cap
- ₹1,11,463 Cr
- Revenue (annual)
- ₹33,700 Cr
- Net profit (annual)
- ₹4,196 Cr
- P/E (TTM)
- 39.8×Sector 46.5×
- Promoter holding
- 26.63%-0.01% QoQ
- FII holding
- 20.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Reddy's Laboratories Ltd
All →Dr. Reddy's Laboratories Business Update
Dr Reddy's says USFDA closed its PAI and GMP inspection at Srikakulam FTO-SEZ Process Unit-02 with VAI classification. The outcome is closed with no monetary penalty.
Dr. Reddy's Laboratories Earnings Call Transcript: Key Takeaways
Revenue declined 1.5% YoY as lower Revlimid sales in North America offset strong double-digit growth in base business and emerging markets.
- Call
- Guides 25% growth
Dr. Reddy's Laboratories Management Change
Dr Reddy's appointed Akhil Ravi as Head API and Services and Senior Management Personnel, effective 13 November 2026. Ravi is the son-in-law of co-chairman G V Prasad.
Dr. Reddy's Laboratories Q2 FY27 Results: Net Profit ₹913.2 Cr, Down 31.7% YoY
Dr. Reddy's Laboratories Ltd reported revenue from operations of ₹8,698 Cr (-1.5% YoY) and net profit of ₹913.2 Cr (-31.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹913.2 Cr · -31.7% YoY
Dr. Reddy's Laboratories Other Announcement
Dr. Reddy's Laboratories Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, including notes on significant beneficial ownership.
Dr. Reddy's Laboratories Regulatory Approval
Dr. Reddy's received DCGI approval for Zytorvi in advanced esophageal cancer, its second Indian indication. This expands first-line immunotherapy access in its oncology portfolio.